

Mark T Ledwidge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1144778/publications.pdf>

Version: 2024-02-01

101
papers

4,234
citations

159525

30
h-index

114418

63
g-index

109
all docs

109
docs citations

109
times ranked

5730
citing authors

#	ARTICLE	IF	CITATIONS
1	Reassuring cardiac and non-cardiac outcomes for heart failure patients managed in a disease management programme during the COVID-19 pandemic. <i>IJC Heart and Vasculature</i> , 2022, 38, 100931.	0.6	1
2	Cardiac MRI e-prime predicts myocardial late gadolinium enhancement and diastolic dysfunction in hypertrophic cardiomyopathy. <i>European Journal of Radiology</i> , 2022, 149, 110192.	1.2	1
3	Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review. <i>Pharmacogenomics Journal</i> , 2022, 22, 89-99.	0.9	12
4	Investigation of association of genetic variant rs3918242 of matrix metalloproteinase-9 with hypertension, myocardial infarction and progression of ventricular dysfunction in Irish Caucasian patients with diabetes: a report from the STOP-HF follow-up programme. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 87.	0.7	8
5	Biomarker profiling for risk of future heart failure (HFpEF) development. <i>Journal of Translational Medicine</i> , 2021, 19, 61.	1.8	21
6	Multiplexed measurement of candidate blood protein biomarkers of heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2248-2258.	1.4	7
7	ECSIT is a critical limiting factor for cardiac function. <i>JCI Insight</i> , 2021, 6, .	2.3	4
8	Aetiology and severity of childhood pneumonia in primary care in Malawi: a cohort study. <i>BMJ Open</i> , 2021, 11, e046633.	0.8	7
9	NT-proBNP/BNP ratio for prognostication in European Caucasian patients enrolled in a heart failure prevention programme. <i>ESC Heart Failure</i> , 2021, 8, 5081-5091.	1.4	6
10	Angiotensin Receptor Neprilysin Inhibitors in HFrEF: Is This the First Disease Modifying Therapy Drug Class Leading to a Substantial Reduction in Diuretic Need?. <i>International Journal of Heart Failure</i> , 2021, 3, 106.	0.9	3
11	426...A systematic review of clinical prediction rules to diagnose bacterial lower respiratory infection in children in primary care and their validation in a new cohort. , 2021, , .		0
12	A Machine Learning Approach for Chronic Heart Failure Diagnosis. <i>Diagnostics</i> , 2021, 11, 1863.	1.3	21
13	A Systematic Review of Clinical Prediction Rules to Predict Hospitalisation in Children with Lower Respiratory Infection in Primary Care and their Validation in a New Cohort. <i>EClinicalMedicine</i> , 2021, 41, 101164.	3.2	2
14	The prehospital patient pathway and experience of care with acute heart failure: a comparison of two health care systems. <i>ESC Heart Failure</i> , 2021, 8, 1076-1084.	1.4	5
15	Reducing Heart Failure Risk in People With Diabetes: The STOP HF Midlands Project. <i>Journal of Cardiac Failure</i> , 2020, 26, 444-445.	0.7	0
16	New-onset heart failure in the STOP-HF programme. Natriuretic peptide defines and tracks risk and enables earlier diagnosis of heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 378-380.	2.9	2
17	Sacubitril-Valsartan in a routine community population: attention to volume status critical to achieving target dose. <i>ESC Heart Failure</i> , 2020, 7, 159-167.	1.4	22
18	Changing to remote management of a community heart failure population during COVID-19 – Clinician and patient perspectives™. <i>IJC Heart and Vasculature</i> , 2020, 31, 100665.	0.6	14

#	ARTICLE	IF	CITATIONS
19	FKBPL is associated with metabolic parameters and is a novel determinant of cardiovascular disease. <i>Scientific Reports</i> , 2020, 10, 21655.	1.6	17
20	Tetranectin, a potential novel diagnostic biomarker of heart failure, is expressed within the myocardium and associates with cardiac fibrosis. <i>Scientific Reports</i> , 2020, 10, 7507.	1.6	17
21	Comparison of longitudinal change in sST2 vs BNP to predict major adverse cardiovascular events in asymptomatic patients in the community. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 6495-6499.	1.6	7
22	Atrial Tissue Pro-Fibrotic M2 Macrophage Marker CD163+, Gene Expression of Procollagen and B-Type Natriuretic Peptide. <i>Journal of the American Heart Association</i> , 2020, 9, e013416.	1.6	23
23	Cardiovascular risk prediction—Are we missing something?. <i>European Journal of Heart Failure</i> , 2020, 22, 1291-1293.	2.9	1
24	Implementing Innovative Approaches to Healthcare in a Lower-Middle Income Country: Perspectives from Malawi. <i>International Journal of General Medicine</i> , 2020, Volume 13, 1723-1730.	0.8	0
25	Nondipping Nocturnal Blood Pressure Predicts Sleep Apnea in Patients With Hypertension. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 957-963.	1.4	31
26	Targeted DNA Methylation Profiling of Human Cardiac Tissue Reveals Novel Epigenetic Traits and Gene Deregulation Across Different Heart Failure Patient Subtypes. <i>Circulation: Heart Failure</i> , 2019, 12, e005765.	1.6	58
27	Developing a disease management program for the improvement of heart failure outcomes: the do's and the don'ts. <i>Expert Review of Cardiovascular Therapy</i> , 2019, 17, 267-273.	0.6	4
28	A systematic review of clinical prediction rules for the diagnosis of chronic heart failure. <i>ESC Heart Failure</i> , 2019, 6, 499-508.	1.4	20
29	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. <i>The Cochrane Library</i> , 2019, 10, CD013015.	1.5	7
30	The Heart Failure Virtual Consultation—a powerful tool for the delivery of specialist care and the democratization of knowledge in the community. <i>European Journal of Heart Failure</i> , 2019, 21, 255-256.	2.9	6
31	Diabetes and complications of the heart in Sub-Saharan Africa: An urgent need for improved awareness, diagnostics and management. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 10-19.	1.1	22
32	B-Type Natriuretic Peptide and Ventricular Dysfunction in the Prediction of Cardiovascular Events and Death in Hypertension. <i>American Journal of Hypertension</i> , 2018, 31, 228-234.	1.0	11
33	Heart Failure in Sub-Saharan Africa. <i>Cardiac Failure Review</i> , 2018, 4, 1.	1.2	23
34	Intrauterine insemination—No more Mr. N.I.C.E. guy?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 210, 342-347.	0.5	15
35	LONGITUDINAL CHANGE IN SOLUBLE ST2 VERSUS B-TYPE NATRIURETIC PEPTIDE IN PREDICTING MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ASYMPTOMATIC PATIENTS IN THE COMMUNITY. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1823.	1.2	0
36	Heart Failure Virtual Consultation: bridging the gap of heart failure care in the community—a mixed methods evaluation. <i>ESC Heart Failure</i> , 2017, 4, 252-258.	1.4	19

#	ARTICLE	IF	CITATIONS
37	Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults. <i>Acta Haematologica</i> , 2017, 138, 223-232.	0.7	11
38	Natriuretic Peptide-based Screening and Prevention of Heart Failure. <i>Cardiac Failure Review</i> , 2017, 3, 83.	1.2	14
39	Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure. <i>Biomarkers</i> , 2016, 21, 538-543.	0.9	6
40	A Central Role for Monocyte-Platelet Interactions in Heart Failure. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 245-261.	1.0	22
41	Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016, 21, 127-137.	1.0	76
42	Heart failure in sub-Saharan Africa: review of the aetiology of heart failure and the role of point-of-care biomarker diagnostics. <i>Tropical Medicine and International Health</i> , 2015, 20, 581-588.	1.0	17
43	Cost-effectiveness of natriuretic peptide-based screening and collaborative care: a report from the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) study. <i>European Journal of Heart Failure</i> , 2015, 17, 672-679.	2.9	42
44	Role of Monitoring Devices in Preventing Heart Failure Admissions. <i>Current Heart Failure Reports</i> , 2015, 12, 269-275.	1.3	3
45	Life expectancy for community-based patients with heart failure from time of diagnosis. <i>International Journal of Cardiology</i> , 2015, 178, 268-274.	0.8	17
46	MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 405-415.	2.9	182
47	Biomarker Testing and Pre-emptive Therapy in Preventing Heart Failure. <i>Current Cardiovascular Risk Reports</i> , 2015, 9, 1.	0.8	0
48	Serum Amyloid P-Component Prevents Cardiac Remodeling in Hypertensive Heart Disease. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 554-566.	1.1	6
49	Exaggerated Inflammation and Monocytosis Associate With Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction: Evidence of M2 Macrophage Activation in Disease Pathogenesis. <i>Journal of Cardiac Failure</i> , 2015, 21, 167-177.	0.7	108
50	The St Vincent's potentially inappropriate medicines study: development of a disease-specific consensus list and its evaluation in ambulatory heart failure care. <i>European Journal of Heart Failure</i> , 2014, 16, 915-922.	2.9	18
51	Nitric oxide-matrix metalloproteinase-9 interactions: Biological and pharmacological significance. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2014, 1843, 603-617.	1.9	79
52	Aspirin Use in Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 243-250.	1.6	19
53	Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. <i>Human Molecular Genetics</i> , 2014, 23, 2176-2188.	1.4	235
54	Extracellular matrix sub-types and mechanical stretch impact human cardiac fibroblast responses to transforming growth factor beta. <i>Connective Tissue Research</i> , 2014, 55, 248-256.	1.1	21

#	ARTICLE	IF	CITATIONS
55	Attenuation of Monocyte Chemotaxis—A Novel Anti-inflammatory Mechanism of Action for the Cardio-protective Hormone B-Type Natriuretic Peptide. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 545-557.	1.1	23
56	Natriuretic Peptide-Based Screening and Collaborative Care for Heart Failure. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 66.	3.8	473
57	Can individualized weight monitoring using the HeartPhone algorithm improve sensitivity for clinical deterioration of heart failure?. <i>European Journal of Heart Failure</i> , 2013, 15, 447-455.	2.9	30
58	Associates of an Elevated Natriuretic Peptide Level in Stable Heart Failure Patients: Implications for Targeted Management. <i>Scientific World Journal</i> , The, 2013, 2013, 1-10.	0.8	6
59	Progression of left atrial volume index in a population at risk for heart failure: a substudy of the STOP-HF (St Vincent's Screening TO Prevent Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 957-964.	2.9	13
60	Screening to prevent heart failure (STOP-HF): expanding the focus beyond asymptomatic left ventricular systolic dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 480-486.	2.9	15
61	In vivo impact of prodrug isosorbide-5-nicotinate-2-aspirinate on lipids and prostaglandin D2: Is this a new immediate-release therapeutic option for niacin?. <i>Atherosclerosis</i> , 2012, 221, 478-483.	0.4	3
62	Differential inhibition of tumour cell-induced platelet aggregation by the nicotinate aspirin prodrug (STO702) and aspirin. <i>British Journal of Pharmacology</i> , 2012, 166, 938-949.	2.7	17
63	Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor- β^2 mediated fibrosis. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, 9.	3.4	48
64	Modest Elevation in BNP in Asymptomatic Hypertensive Patients Reflects Sub-Clinical Cardiac Remodeling, Inflammation and Extracellular Matrix Changes. <i>PLoS ONE</i> , 2012, 7, e49259.	1.1	39
65	Long-Term Statin Therapy in Patients With Systolic Heart Failure and Normal Cholesterol: Effects on Elevated Serum Markers of Collagen Turnover, Inflammation, and B-Type Natriuretic Peptide. <i>Clinical Therapeutics</i> , 2012, 34, 91-100.	1.1	38
66	Mechanisms of aggregation inhibition by aspirin and nitrate-aspirin prodrugs in human platelets. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 64, 77-89.	1.2	8
67	Prospective Analysis of LDL-C Goal Achievement and Self-Reported Medication Adherence Among Statin Users in Primary Care. <i>Clinical Therapeutics</i> , 2011, 33, 1180-1189.	1.1	41
68	The authors respond:. <i>Clinical Therapeutics</i> , 2011, 33, 2090.	1.1	0
69	Clinical and psychological impact of prophylactic implantable cardioverter-defibrillators in a community heart failure population. <i>Irish Journal of Medical Science</i> , 2011, 180, 369-374.	0.8	3
70	Are beta-agonists responsible for increased mortality in heart failure?. <i>European Journal of Heart Failure</i> , 2011, 13, 885-891.	2.9	37
71	Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?. <i>European Journal of Heart Failure</i> , 2011, 13, 1087-1095.	2.9	168
72	B-type natriuretic peptide measurement in primary care; magnitude of associations with cardiovascular risk factors and their therapies. Observations from the STOP-HF (St. Vincent's) Tj ETQq0 0 0 rgBI. # Overlock 10 Tf 50		

#	ARTICLE	IF	CITATIONS
73	Proteomic Analysis of Coronary Sinus Serum Reveals Leucine-Rich Î±2-Glycoprotein as a Novel Biomarker of Ventricular Dysfunction and Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 188-197.	1.6	68
74	Quality of life predicts outcome in a heart failure disease management program. <i>International Journal of Cardiology</i> , 2010, 139, 60-67.	0.8	38
75	Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover. <i>European Journal of Heart Failure</i> , 2009, 11, 191-197.	2.9	107
76	Natural History of Markers of Collagen Turnover in Patients With Early Diastolic Dysfunction and Impact of Eplerenone. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1674-1682.	1.2	116
77	Multiple Neurohumoral Modulating Agents in Systolic Dysfunction Heart Failure: Are We Lowering Blood Pressure Too Much?. <i>Journal of Cardiac Failure</i> , 2008, 14, 555-560.	0.7	19
78	Outpatient intravenous diuretic therapy; potential for marked reduction in hospitalisations for acute decompensated heart failure. <i>European Journal of Heart Failure</i> , 2008, 10, 267-272.	2.9	61
79	Need and evolution of need for device therapy in a community heart failure population. <i>European Journal of Heart Failure</i> , 2008, 10, 601-607.	2.9	3
80	Improvement but no cure of left ventricular systolic dysfunction in treated heart failure patients. <i>European Journal of Heart Failure</i> , 2007, 9, 1196-1204.	2.9	12
81	Disease management programs for heart failure: Not just for the "sick" heart failure population. <i>European Journal of Heart Failure</i> , 2007, 9, 113-117.	2.9	18
82	Diastolic Heart Failure. <i>Circulation</i> , 2007, 115, 888-895.	1.6	407
83	The Biologic Variability of B-Type Natriuretic Peptide and N-Terminal Pro-B-Type Natriuretic Peptide in Stable Heart Failure Patients. <i>Journal of Cardiac Failure</i> , 2007, 13, 50-55.	0.7	118
84	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 753-762.	1.2	203
85	Fluid Restriction in the Management of Decompensated Heart Failure: No Impact on Time to Clinical Stability. <i>Journal of Cardiac Failure</i> , 2007, 13, 128-132.	0.7	70
86	Decompensation of Chronic Heart Failure Associated With Pregabalin in Patients With Neuropathic Pain. <i>Journal of Cardiac Failure</i> , 2007, 13, 227-229.	0.7	53
87	Community Direct Access Service for Early Detection and Treatment of Clinical Deterioration. <i>Disease Management and Health Outcomes</i> , 2006, 14, 185-190.	0.3	3
88	Progression of preserved systolic function heart failure to systolic dysfunction " A natural history study. <i>International Journal of Cardiology</i> , 2006, 106, 95-102.	0.8	26
89	Heart failure care in a hospital unit: a comparison of standard 3-month and extended 6-month programs. <i>European Journal of Heart Failure</i> , 2005, 7, 385-391.	2.9	25
90	Clinical deterioration in established heart failure: What is the value of BNP and weight gain in aiding diagnosis?. <i>European Journal of Heart Failure</i> , 2005, 7, 953-957.	2.9	150

#	ARTICLE	IF	CITATIONS
91	Specialist care of heart failure improves appropriate pharmacotherapy at the expense of greater polypharmacy and drug-interactions. <i>European Journal of Heart Failure</i> , 2004, 6, 235-243.	2.9	35
92	Heart failure management programs: Can we afford to ignore the inpatient phase of care?. <i>Journal of Cardiac Failure</i> , 2003, 9, 258-262.	0.7	13
93	Specialist Nurse Supervised In-Hospital Titration to Target Dose ACE Inhibitor – Is It Safe and Feasible in a Community Heart Failure Population?. <i>European Journal of Cardiovascular Nursing</i> , 2003, 2, 183-188.	0.4	10
94	Multidisciplinary Care of Heart Failure: What Have We Learned and Where Can We Improve?. <i>European Journal of Cardiovascular Nursing</i> , 2003, 2, 247-249.	0.4	5
95	Is multidisciplinary care of heart failure cost-beneficial when combined with optimal medical care?. <i>European Journal of Heart Failure</i> , 2003, 5, 381-389.	2.9	68
96	Heart failure management: Multidisciplinary care has intrinsic benefit above the optimization of medical care. <i>Journal of Cardiac Failure</i> , 2002, 8, 142-148.	0.7	139
97	Elimination of early rehospitalization in a randomized, controlled trial of multidisciplinary care in a high-risk, elderly heart failure population: the potential contributions of specialist care, clinical stability and optimal angiotensin-converting enzy. <i>European Journal of Heart Failure</i> , 2001, 3, 209-215.	2.9	81
98	Effects of surface active characteristics and solid state forms on the pH solubility profiles of drug – salt systems. <i>International Journal of Pharmaceutics</i> , 1998, 174, 187-200.	2.6	79
99	Effects of environmental factors on the dehydration of diclofenac HEP dihydrate and theophylline monohydrate. <i>International Journal of Pharmaceutics</i> , 1997, 147, 41-49.	2.6	15
100	Physicochemical Characterization of Diclofenac N-(2-Hydroxyethyl)pyrrolidine: Anhydrate and Dihydrate Crystalline Forms. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 16-21.	1.6	29
101	Natriuretic peptide-guided treatment for the prevention of cardiovascular events in patients without heart failure. <i>The Cochrane Library</i> , 0, , .	1.5	0